Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus MINIZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus MINIZIDE.
DEMI-REGROTON vs MINIZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination